BridgeBio Pharma Statistics Share Statistics BridgeBio Pharma has 191.17M
shares outstanding. The number of shares has increased by 0.98%
in one year.
Shares Outstanding 191.17M Shares Change (YoY) 0.98% Shares Change (QoQ) -0.16% Owned by Institutions (%) 97.35% Shares Floating 161.95M Failed to Deliver (FTD) Shares 9,611 FTD / Avg. Volume 0.32%
Short Selling Information The latest short interest is 19.48M, so 10.26% of the outstanding
shares have been sold short.
Short Interest 19.48M Short % of Shares Out 10.26% Short % of Float 17.29% Short Ratio (days to cover) 7.04
Valuation Ratios The PE ratio is -9.53 and the forward
PE ratio is -26.94.
BridgeBio Pharma's PEG ratio is
0.35.
PE Ratio -9.53 Forward PE -26.94 PS Ratio 23.01 Forward PS 11.5 PB Ratio -3.5 P/FCF Ratio -9.79 PEG Ratio 0.35
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BridgeBio Pharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.67,
with a Debt / Equity ratio of -1.19.
Current Ratio 4.67 Quick Ratio 4.67 Debt / Equity -1.19 Debt / EBITDA -3.96 Debt / FCF -3.32 Interest Coverage -5.97
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $306.07K Profits Per Employee $-738.98K Employee Count 725 Asset Turnover 0.24 Inventory Turnover n/a
Taxes Income Tax 1.15M Effective Tax Rate -0.21%
Stock Price Statistics The stock price has increased by 100.5% in the
last 52 weeks. The beta is 1.23, so BridgeBio Pharma's
price volatility has been higher than the market average.
Beta 1.23 52-Week Price Change 100.5% 50-Day Moving Average 43.34 200-Day Moving Average 34.32 Relative Strength Index (RSI) 54.28 Average Volume (20 Days) 2,998,458
Income Statement In the last 12 months, BridgeBio Pharma had revenue of 221.9M
and earned -535.76M
in profits. Earnings per share was -2.88.
Revenue 221.9M Gross Profit 218.02M Operating Income -592.97M Net Income -535.76M EBITDA -436.83M EBIT -442.9M Earnings Per Share (EPS) -2.88
Full Income Statement Balance Sheet The company has 681.1M in cash and 1.73B in
debt, giving a net cash position of -1.05B.
Cash & Cash Equivalents 681.1M Total Debt 1.73B Net Cash -1.05B Retained Earnings -3.1B Total Assets 1.08B Working Capital 736.42M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -520.73M
and capital expenditures -933K, giving a free cash flow of -521.66M.
Operating Cash Flow -520.73M Capital Expenditures -933K Free Cash Flow -521.66M FCF Per Share -2.8
Full Cash Flow Statement Margins Gross margin is 98.25%, with operating and profit margins of -267.22% and -241.44%.
Gross Margin 98.25% Operating Margin -267.22% Pretax Margin -244.34% Profit Margin -241.44% EBITDA Margin -196.86% EBIT Margin -267.22% FCF Margin -235.09%
